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Ovarian failure (OF) at age !40 years occurs in ∼1% of all women. Other than karyotype abnormalities, very few
genes are known to be associated with this ovarian dysfunction. We studied eight patients who presented with
premature OF and white-matter abnormalities on magnetic resonance imaging. Neurological signs may be absent
or present after OF. In seven patients, we report for the first time mutations in three of the five EIF2B genes (EIF2B2,
-4, and -5) that were recently shown to cause childhood ataxia with central nervous system hypomyelination/
vanishing white-matter disease leukodystrophy. The correlation we observed between the age at onset of the
neurological deterioration and the severity of OF suggests a common pathophysiological pathway.
Ovarian failure (OF) can be expressed as primary amen-
orrhea or as secondary amenorrhea lasting 16 mo, as-
sociated with elevated gonadotrophin levels at age !40
years. Premature OF affects 1% of all women and occurs
in 0.1% at age !30 years (Coulam et al. 1986). OF has
been associated with karyotype abnormalities, includ-
ing various X chromosome aberrations (POFX [MIM
31360]; Shelling 2000), such as Turner syndrome, which
causes depletion of ovarian follicles during development.
Although such conditions as autoimmune diseases or
diabetes mellitus are also associated with OF, the cause
is unknown in ∼95% of cases. However, since many
affected women have a family history of the condition,
predisposition to OF may be inherited (Conway 1997).
To date, mutations associated with OF have been
identified in a small number of genes (Schlessinger et
al. 2002), including those that encode the inhibin
alpha (INHA [MIM 147380]) (Shelling et al. 2000),
the follicle-stimulating hormone receptor (FSHR; MIM
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136435) (Aittoma¨ki et al. 1995), the luteinizing hor-
mone/choriogonadotrophin receptor (LHCGR [MIM
152790]) (Latronico et al. 1996), and the forkhead tran-
scription factor 2 (FOXL2 [MIM 605597]) (Harris et
al. 2002). In FOXL2 mutations, OF is associated with
blepharophimosis-ptosis-epicanthus inversus syndrome
(BPES [MIM 110100]) (Harris et al. 2002). Mutations
in these various genes are present in !10% of patients
with OF (Harris et al. 2002).
Elsewhere, we have described four patients with
the unusual association of OF with white-matter ab-
normalities observed on cerebral magnetic resonance
imaging (MRI), and we have termed the condition “ova-
rioleukodystrophy” (Schiffmann et al. 1997). Similari-
ties of the cerebral abnormalities to those in patients
with childhood ataxia with CNS hypomyelination
(CACH)/vanishing white-matter leukodystrophy (VWM
[OMIM 603896]; Schiffmann et al. 1994; van der Knaap
et al. 1997) led us to test eight patients with ovarioleu-
kodystrophy for mutations in the five subunits (a–) of
the eukaryotic translation initiation factor 2B (eIF2B),
which was recently found to be mutated in CACH/
VWM (Leegwater et al. 2001; van der Knaap et al.
2002).
Eight patients from seven families were identified on
the basis of unusual association of OF with white-matter
abnormalities. The diagnosis of OF has been confirmed
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by findings of high basal gonadotrophin levels and low
estrogen and progesterone levels. All the patients had a
normal karyotype. Clinical characteristics of patients are
reported in table 1. Only patient 871 had consanguin-
eous parents (first cousins from Algeria). In the three
patients with primary amenorrhea (941-1, 992, and
943), school difficulties, together with poor fine motor
performance, were present prior to the development of
a slowly progressive neurological disease in adolescence.
Only patient 943 presented with rapid cognitive decline,
including a frontal lobe syndrome. The age at menarche
was normal in the five patients with secondary amen-
orrhea (941-2, 944, 871, 948, and 1014). Two patients
(941-2 and 944), who never acquired regular menstrual
cycles, had school difficulties and developed progressive
motor deterioration after adolescence. In contrast, three
other patients (871, 948, and 1014), who had regular
menstrual cycles, attended high school with no difficulty;
two presented with neurological dysfunction in their 30s
(patients 871 and 948), and the third (patient 1014) had
normal neurological and cognitive functions when re-
current headaches at 16 years of age led to the incidental
discovery of white-matter abnormalities during cerebral
MRI. In all instances, except patient 943, an abnormal
diffuse signal in the hemispheric white matter was ob-
served during MRI (fig. 1). Six patients (941-1, 941-2,
944, 992, 871, and 948) had abnormal signal (similar
to that found in cerebrospinal fluid) within the abnormal
white matter when tested by use of fluid-attenuated in-
version recovery (FLAIR) sequence imaging. These ab-
normalities were identical to those seen in patients with
CACH/VWM, although the cavitation process was less
extensive than in the typical form of CACH/VWM and
was restricted to the frontal region in four patients (941-
1, 941-2, 944, and 948) (fig. 1). In contrast to the typical
form of CACH/VWM, atrophy was observed in the ce-
rebral cortex, hemispheric white matter, and corpus cal-
losum; atrophy extended to the brain stem or the cer-
ebellum in two patients (941-1 and 941-2) (fig. 1). The
MRI abnormalities did not significantly change during
the 8-year follow-up of patients 941-1, 941-2, and 992.
The similarities of the cerebral MRI abnormalities
observed in our patients with OF to those in patients
with CACH/VWM led us to test the five EIF2B genes
recently found to be mutated in patients with CACH/
VWM (EIF2B1 [GenBank accession number NM
001414], EIF2B2 [MIM 606454; GenBank accession
number NM 014239; region 14q24.3], EIF2B3
[GenBank accession number NM 020365], EIF2B4
[MIM 606687; GenBank accession number NM
015636; region 2p23], and EIF2B5 [MIM 603945;
GenBank accession number XM 029136; region 3q28])
(Leegwater et al. 2001; van der Knaap et al. 2002). We
sequenced all the coding regions of the five EIF2B genes
(including 39–173 nt of the intronic regions) in these
eight affected patients, as described elsewhere (van der
Knaap et al. 2002; modified primer sequences available
upon request). All the identified mutations are reported
in table 1. Mutations were found in EIF2B genes in all
the patients except patient 943: four mutations were in
the EIF2B2 gene (patients 944 and 992); two were in
the EIF2B4 gene (patients 941-1 and 941-2, who are
sisters); and two were in the EIF2B5 gene (patients 948,
871, and 1014). These mutations were not found in a
control group composed of 320 chromosomes of indi-
viduals from the same populations, which were of north-
ern European and North African descent. Patients 871
and 948 had an R113H homozygous missense mutation
in the  subunit of eIF2B. In the four other families,
patients were compound heterozygotes for different mu-
tations: six were missense mutations (including one pa-
tient with the R113H mutation), and one was a frame-
shift mutation.
The eIF2B protein is composed of five subunits (a–e)
and converts the protein synthesis initiation factor 2
(eIF2) from an inactive GDP-bound form to an active
eIF2-GTP complex (Gomez and Pavitt 2000), allowing
the formation of the 43S complex, precursor of the pro-
tein translation initiation. Although eIF2B is a ubiqui-
tous protein, its mutations were previously described
as affecting only the brain white matter. In the present
study, we report OF due to eIF2B mutations in seven
patients. The only patient without identified EIF2Bmu-
tations (patient 943) had a distinctive neurological pre-
sentation that included cognitive deterioration without
motor signs and with white-matter abnormalities re-
stricted to the frontal lobes. Further analyses are needed
to rule out mutations in the intronic and regulatory
regions of the five EIF2B genes. However, the distinctive
neurological presentations suggest that another gene
could be involved in this patient’s OF.
The seven patients with OF and eIF2B mutations have
diffuse white-matter abnormalities, which are detected
by use of cerebral MRI. Six developed neurological de-
terioration with progressive urinary, speech, and gait dis-
turbances. The age at onset of the neurological deteri-
oration correlated positively with the severity of the
ovarian dysfunction, and OF can precede the neurolog-
ical decline, as was observed in patient 948. Further
analyses are needed to determine if EIF2B genes mu-
tations are responsible for a significant percentage of
apparently isolated OF.
For EIF2B2 and EIF2B4, the combinations of het-
erozygous mutations found in our patients with ovario-
leukodystrophy were different from those described in
a pool of patients with CACH/VWM (van der Knaap
et al. 2002). Five mutations have not been reported
before: S171F and R183stop (EIF2B2), C465R and
Y489H (EIF2B4), and R195C (EIF2B5) (table 1).
Three of the six families with OF carry an R113H
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Figure 1 Cerebral MRI of affected patients. Images of patients 941-2 (A, B, and C), 944 (D, E, and F), and 1014 (G, H, and I), obtained
when patients were, respectively, 24, 33, and 16 years of age. In the hemispheric white matter, the following anomalies were observed: an
abnormal diffuse signal, characterized by a decreased signal on T1 weighted sequence imaging (A, D, E, and G) and an increased signal on
T2 (B and H) and on fluid attenuated inversion recovery (FLAIR) sequences imaging (C, F, and I). Patients 941-2 and 944, who had early
school difficulties, have cerebral atrophy involving the cerebral cortex, hemispheric white matter (with ventricular dilatation), and corpus
callosum. Abnormal signal within the abnormal white matter on FLAIR sequence imaging is extensive in the frontal white matter of patient
941-2 (C, arrowhead), limited in patient 944 (F, arrowhead), and absent in patient 1014, who experienced secondary amenorrhea and episodes
of headache but had normal results on neurological examination at age 16 years.
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mutation in the  subunit of eIF2B, which is the guanine
nucleotide exchange factor of the protein. Patients from
these families have the mildest forms of the disease. The
R113H mutation in EIF2B5 has also been found in 22%
of chromosomes of 41 patients with CACH/VWM
(Leegwater et al. 2001). Because the arginine at position
113 is not conserved among species and because histi-
dine is found at this position in the rat and mouse, the
homozygous R113H mutation observed in humans (pa-
tients 871 and 948) may not strongly affect the eIF2B
protein function. The third patient (1014), who had
early secondary amenorrhea, is a compound heterozy-
gote of R113H and an unreported R195C mutation.
Since the arginine at position 195 of the  subunit of
eIF2B is highly conserved among species (from yeast to
humans), its substitution by cytidine may more pro-
foundly disturb the function of this protein. We recently
found that individuals from two indigenous North
American populations, the Cree and the Chippewa, have
a particularly severe form of leukodystrophy and are
homozygous for a mutation at the same arginine 195
residue but substituted by histidine (R195H) (Fogli et
al. 2002). In this severe form of the eIF2B mutation, as
well as in the classical form of CACH/VWM, patients
do not survive to puberty and therefore do not express
OF. However, several reports in the literature suggest
that ovarian dysgenesis may be present in these patients.
Two children with neuropathological abnormalities sug-
gestive of CACH/VWM were also found at autopsy to
have “ovarian dysgenesis” (Boltshauser et al. 2002) or
“bilateral streak ovaries” (van der Knaap 1997). In ad-
dition, OF was reported in two sisters who presented
with primary amenorrhea and behavior problems at ages
130 years, with subsequent neurological deterioration,
white-matter abnormalities (detected during cerebral
MRI), and pigmentary orthochromatic leukodystrophy
(observed at autopsy) (Verghese et al. 2002).
The upper limit of reproductive life span is predeter-
mined at birth, because all of the follicles that a woman
will have in adult life are formed in utero. The number
of primordial follicles reaches a maximum of 7 million
at 5 mo gestation, whereas it declines to ∼2 million at
birth and to ∼400,000 at puberty (Christin-Maitre et al.
1998). That pool supplies the ovulatory follicles after
menarche and is depleted until it falls below a threshold
value of 1,000 follicles, and menopause ensues (Faddy
2000). Therefore, 199% of the follicles from the initial
pool will undergo atresia, with apoptosis being the most
important phenomenon controlling this atresia (Chris-
tin-Maitre et al. 1998). Premature OF could result from
a decrease in the number of follicles formed, an increase
in the rate of follicle loss, an alteration in the recruitment
of the follicle, or an interruption in the maturation of
the follicle. In BPES due to FOXL2mutation, the ovarian
dysfunction and the eyelid phenotype can be explained
by the restricted expression of the mutated FOXL2 gene
in these cell types during development (Crisponi et al.
2001). Although eIF2B is a ubiquitous protein, its mu-
tations, for still unexplained reasons, seem to affect only
the CNS and ovary in the patients we have reported
here. The correlation observed between the age at onset
of the neurological deterioration and the severity of
OF suggests a common pathophysiological pathway.
The potential role of eIF2B in the formation of follicles
and glial cells has not yet been reported. In both tissues,
successive programmed cell death occurs during devel-
opment, and defects in regulation of intracellular death
effectors, such as caspase-2, can affect both tissues
(Bergeron et al. 1998). The role of eIF2B in apoptosis
is presently unknown. However, in the brains of patients
with CACH/VWM, apoptosis of mature oligodendro-
cytes, as determined by use of morphological criteria,
has been reported only once (Bru¨ck et al. 2001), whereas
an increase in the number of mature oligodendocytes
that have foamy aspects but lack apoptotic features has
been frequently reported (Rodriguez et al. 1999; Wong
et al. 2000). In addition, in a particularly severe form
of CACH/VWM, no abnormalities have been found by
use of TUNEL and P53 labeling (Francalanci et al.
2001). eIF2B is an important regulatory pathway for the
prevention of synthesis of denatured proteins during cel-
lular stress, and it functions in parallel with the pro-
duction of heat shock proteins (Proud et al. 2002). In
patients with eIF2B mutations, a high susceptibility to
cellular stress is suggested by the acute phase of neuro-
logical deterioration observed after minor head trauma
or common viral infections. Knockout mice for the heat
shock factor 2 (Hsf2), a transcriptional regulator of heat
shock gene expression, are infertile because of the in-
creased apoptosis of ovarian follicles that is associated
with brain abnormalities, an observation suggestive of
defects in glial cell development (Kallio et al. 2002).
Similarly, eIF2B dysfunction in humans may be respon-
sible for increased apoptosis of ovarian follicles (leading
to OF) and for a defect in glial cell development (causing
abnormal formation of white-matter structures). This
abnormal CNS development would increase suscep-
tibility of eIF2B-mutated cells to cellular stress, with
subsequent progressive neurological deterioration and
white-matter cavitation. Estrogen deprivation due to OF
may accelerate this deterioration by increasing the vul-
nerability of neurons to injury (Liu et al. 2001).
In conclusion, we report an association of white-mat-
ter disease with OF in seven patients with mutations in
the EIF2B genes. Further investigation may show that
defects in this gene are the basis of some cases of OF of
unknown cause. The correlation we observed between
the age at onset of the neurological deterioration and
the severity of the OF suggests a common pathophysio-
logical pathway in these two tissue types that is mediated
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by eIF2B and result from dysgenesis during development
and/or abnormal response to stress in the adult.
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